57 related articles for article (PubMed ID: 7514956)
1. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
2. Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome.
Sottile ML; Gómez LC; Redondo A; Ibarra J; García MB; Gonzalez L; Vargas-Roig LM; Nadin SB
J Histochem Cytochem; 2024 Mar; 72(3):173-188. PubMed ID: 38439738
[TBL] [Abstract][Full Text] [Related]
3. DNA Adducts in Cancer Chemotherapy.
Li Y
J Med Chem; 2024 Apr; 67(7):5113-5143. PubMed ID: 38552031
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
5. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.
Wang SS; Zimmermann M; Zhang H; Lin TY; Malfatti M; Haack K; Turteltaub KW; Cimino GD; de Vere White R; Pan CX; Henderson PT
Int J Cancer; 2017 Aug; 141(3):604-613. PubMed ID: 28437852
[TBL] [Abstract][Full Text] [Related]
6. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.
Stornetta A; Zimmermann M; Cimino GD; Henderson PT; Sturla SJ
Chem Res Toxicol; 2017 Jan; 30(1):388-409. PubMed ID: 27936622
[TBL] [Abstract][Full Text] [Related]
7. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Zimmermann M; Wang SS; Zhang H; Lin TY; Malfatti M; Haack K; Ognibene T; Yang H; Airhart S; Turteltaub KW; Cimino GD; Tepper CG; Drakaki A; Chamie K; de Vere White R; Pan CX; Henderson PT
Mol Cancer Ther; 2017 Feb; 16(2):376-387. PubMed ID: 27903751
[TBL] [Abstract][Full Text] [Related]
8. Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.
Enright HA; Malfatti MA; Zimmermann M; Ognibene T; Henderson P; Turteltaub KW
Chem Res Toxicol; 2016 Dec; 29(12):1976-1986. PubMed ID: 27726383
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
Cimino GD; Pan CX; Henderson PT
Bioanalysis; 2013 Feb; 5(3):369-91. PubMed ID: 23394702
[TBL] [Abstract][Full Text] [Related]
10. Progress in personalizing chemotherapy for bladder cancer.
Chang JS; Lara PN; Pan CX
Adv Urol; 2012; 2012():364919. PubMed ID: 22400017
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of DNA adduct formation in the oral cavity after drinking alcohol.
Balbo S; Meng L; Bliss RL; Jensen JA; Hatsukami DK; Hecht SS
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):601-8. PubMed ID: 22301829
[TBL] [Abstract][Full Text] [Related]
12. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.
Henderson PT; Li T; He M; Zhang H; Malfatti M; Gandara D; Grimminger PP; Danenberg KD; Beckett L; de Vere White RW; Turteltaub KW; Pan CX
Int J Cancer; 2011 Sep; 129(6):1425-34. PubMed ID: 21128223
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
Wang S; Zhang H; Malfatti M; de Vere White R; Lara PN; Turteltaub K; Henderson P; Pan CX
Chem Res Toxicol; 2010 Nov; 23(11):1653-5. PubMed ID: 21028869
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide excision repair and anti-cancer chemotherapy.
Reed E
Cytotechnology; 1998 Sep; 27(1-3):187-201. PubMed ID: 19002792
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
Pieck AC; Drescher A; Wiesmann KG; Messerschmidt J; Weber G; Strumberg D; Hilger RA; Scheulen ME; Jaehde U
Br J Cancer; 2008 Jun; 98(12):1959-65. PubMed ID: 18506148
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.
Thomas G; Ali S; Hoebers FJ; Darcy KM; Rodgers WH; Patel M; Abulafia O; Lucci JA; Begg AC
Gynecol Oncol; 2008 Feb; 108(2):317-25. PubMed ID: 18037478
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
